Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 6 of 6 entries
Sorted by: Best Match Show Resources per page
Segmental facial infantile haemangiomas in the era of propranolol: evaluation at 6 years of age.

Journal of the European Academy of Dermatology and Venereology : JEADV

Letertre O, Boccara O, Prey S, Pedespan JM, Boralevi F, Léauté-Labrèze C.
PMID: 35000215
J Eur Acad Dermatol Venereol. 2022 Jan 09; doi: 10.1111/jdv.17907. Epub 2022 Jan 09.

BACKGROUND: The long-term evolution of children with segmental facial infantile haemangioma (SFIH) treated with propranolol remains unstudied.OBJECTIVES: The objective of this study was to evaluate the neurodevelopmental features of children with SFIH treated with propranolol at 6 years of...

Cite
Letertre O, Boccara O, Prey S, et al. Segmental facial infantile haemangiomas in the era of propranolol: evaluation at 6 years of age. J Eur Acad Dermatol Venereol. 2022;doi: 10.1111/jdv.17907.
Letertre, O., Boccara, O., Prey, S., Pedespan, J. M., Boralevi, F., & Léauté-Labrèze, C. (2022). Segmental facial infantile haemangiomas in the era of propranolol: evaluation at 6 years of age. Journal of the European Academy of Dermatology and Venereology : JEADV, . https://doi.org/10.1111/jdv.17907
Letertre, O, et al. "Segmental facial infantile haemangiomas in the era of propranolol: evaluation at 6 years of age." Journal of the European Academy of Dermatology and Venereology : JEADV vol. (2022). doi: https://doi.org/10.1111/jdv.17907
Letertre O, Boccara O, Prey S, Pedespan JM, Boralevi F, Léauté-Labrèze C. Segmental facial infantile haemangiomas in the era of propranolol: evaluation at 6 years of age. J Eur Acad Dermatol Venereol. 2022 Jan 09; doi: 10.1111/jdv.17907. Epub 2022 Jan 09. PMID: 35000215.
Copy Download .nbib Format: NLM
Segmental facial infantile haemangiomas in the era of propranolol: evaluation at 6 years of age.

Journal of the European Academy of Dermatology and Venereology : JEADV

Letertre O, Boccara O, Prey S, Pedespan JM, Boralevi F, Léauté-Labrèze C.
PMID: 35000215
J Eur Acad Dermatol Venereol. 2022 Jan 09; doi: 10.1111/jdv.17907. Epub 2022 Jan 09.

BACKGROUND: The long-term evolution of children with segmental facial infantile haemangioma (SFIH) treated with propranolol remains unstudied.OBJECTIVES: The objective of this study was to evaluate the neurodevelopmental features of children with SFIH treated with propranolol at 6 years of...

Cite
Letertre O, Boccara O, Prey S, et al. Segmental facial infantile haemangiomas in the era of propranolol: evaluation at 6 years of age. J Eur Acad Dermatol Venereol. 2022;doi: 10.1111/jdv.17907.
Letertre, O., Boccara, O., Prey, S., Pedespan, J. M., Boralevi, F., & Léauté-Labrèze, C. (2022). Segmental facial infantile haemangiomas in the era of propranolol: evaluation at 6 years of age. Journal of the European Academy of Dermatology and Venereology : JEADV, . https://doi.org/10.1111/jdv.17907
Letertre, O, et al. "Segmental facial infantile haemangiomas in the era of propranolol: evaluation at 6 years of age." Journal of the European Academy of Dermatology and Venereology : JEADV vol. (2022). doi: https://doi.org/10.1111/jdv.17907
Letertre O, Boccara O, Prey S, Pedespan JM, Boralevi F, Léauté-Labrèze C. Segmental facial infantile haemangiomas in the era of propranolol: evaluation at 6 years of age. J Eur Acad Dermatol Venereol. 2022 Jan 09; doi: 10.1111/jdv.17907. Epub 2022 Jan 09. PMID: 35000215.
Copy Download .nbib Format: NLM
Slow Titration of Cannabidiol Add-On in Drug-Resistant Epilepsies Can Improve Safety With Maintained Efficacy in an Open-Label Study.

Frontiers in neurology

D'Onofrio G, Kuchenbuch M, Hachon-Le Camus C, Desnous B, Staath V, Napuri S, Ville D, Pedespan JM, Lépine A, Cances C, de Saint-Martin A, Teng T, Chemaly N, Milh M, Villeneuve N, Nabbout R.
PMID: 32903409
Front Neurol. 2020 Aug 12;11:829. doi: 10.3389/fneur.2020.00829. eCollection 2020.

No abstract available.

Cite
D'Onofrio G, Kuchenbuch M, Hachon-Le Camus C, et al. Slow Titration of Cannabidiol Add-On in Drug-Resistant Epilepsies Can Improve Safety With Maintained Efficacy in an Open-Label Study. Front Neurol. 2020;11:829doi: 10.3389/fneur.2020.00829.
D'Onofrio, G., Kuchenbuch, M., Hachon-Le Camus, C., Desnous, B., Staath, V., Napuri, S., Ville, D., Pedespan, J. M., Lépine, A., Cances, C., de Saint-Martin, A., Teng, T., Chemaly, N., Milh, M., Villeneuve, N., & Nabbout, R. (2020). Slow Titration of Cannabidiol Add-On in Drug-Resistant Epilepsies Can Improve Safety With Maintained Efficacy in an Open-Label Study. Frontiers in neurology, 11829. https://doi.org/10.3389/fneur.2020.00829
D'Onofrio, Gianluca, et al. "Slow Titration of Cannabidiol Add-On in Drug-Resistant Epilepsies Can Improve Safety With Maintained Efficacy in an Open-Label Study." Frontiers in neurology vol. 11 (2020): 829. doi: https://doi.org/10.3389/fneur.2020.00829
D'Onofrio G, Kuchenbuch M, Hachon-Le Camus C, Desnous B, Staath V, Napuri S, Ville D, Pedespan JM, Lépine A, Cances C, de Saint-Martin A, Teng T, Chemaly N, Milh M, Villeneuve N, Nabbout R. Slow Titration of Cannabidiol Add-On in Drug-Resistant Epilepsies Can Improve Safety With Maintained Efficacy in an Open-Label Study. Front Neurol. 2020 Aug 12;11:829. doi: 10.3389/fneur.2020.00829. eCollection 2020. PMID: 32903409; PMCID: PMC7434926.
Copy Download .nbib Format: NLM
[Multiple sclerosis: pathogenesis and manifestations in children].

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie

Brissaud O, Palin K, Chateil JF, Pedespan JM.
PMID: 11582940
Arch Pediatr. 2001 Sep;8(9):969-78. doi: 10.1016/s0929-693x(01)00564-4.

Multiple sclerosis (MS) is rare in children and occurs exceptionally before ten years. Sex ratio (girl/boy) is around 2.5 to 3, higher than in adults. Brain stem dysfunction and meningeal symptoms are more commonly first manifestations of the disease...

Cite
Brissaud O, Palin K, Chateil JF, et al. Sclérose en plaques: pathogénie et formes de révélation chez l'enfant. [Multiple sclerosis: pathogenesis and manifestations in children]. Arch Pediatr. 2001;8(9):969-78doi: 10.1016/s0929-693x(01)00564-4.
Brissaud, O., Palin, K., Chateil, J. F., & Pedespan, J. M. (2001). Sclérose en plaques: pathogénie et formes de révélation chez l'enfant. [Multiple sclerosis: pathogenesis and manifestations in children]. Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 8(9), 969-78. https://doi.org/10.1016/s0929-693x(01)00564-4
Brissaud, O, et al. "Sclérose en plaques: pathogénie et formes de révélation chez l'enfant." [Multiple sclerosis: pathogenesis and manifestations in children]. Archives de pediatrie : organe officiel de la Societe francaise de pediatrie vol. 8,9 (2001): 969-78. doi: https://doi.org/10.1016/s0929-693x(01)00564-4
Brissaud O, Palin K, Chateil JF, Pedespan JM. Sclérose en plaques: pathogénie et formes de révélation chez l'enfant. [Multiple sclerosis: pathogenesis and manifestations in children]. Arch Pediatr. 2001 Sep;8(9):969-78. doi: 10.1016/s0929-693x(01)00564-4. French. PMID: 11582940.
Copy Download .nbib Format: NLM
Segmental facial infantile hemangiomas in the era of propranolol: evaluation at six years of age.

Journal of the European Academy of Dermatology and Venereology : JEADV

Letertre O, Boccara O, Prey S, Pedespan JM, Boralevi F, Léauté-Labrèze C.
PMID: 35000215
J Eur Acad Dermatol Venereol. 2022 Jan 09; doi: 10.1111/jdv.17907. Epub 2022 Jan 09.

BACKGROUND: The long-term evolution of children with Segmental Facial Infantile Hemangioma (SFIH) treated with propranolol remains unstudied.OBJECTIVES: To evaluate the neurodevelopmental features of children with SFIH treated with propranolol at six years of age.METHODS: This retrospective case series study...

Cite
Letertre O, Boccara O, Prey S, et al. Segmental facial infantile hemangiomas in the era of propranolol: evaluation at six years of age. J Eur Acad Dermatol Venereol. 2022;doi: 10.1111/jdv.17907.
Letertre, O., Boccara, O., Prey, S., Pedespan, J. M., Boralevi, F., & Léauté-Labrèze, C. (2022). Segmental facial infantile hemangiomas in the era of propranolol: evaluation at six years of age. Journal of the European Academy of Dermatology and Venereology : JEADV, . https://doi.org/10.1111/jdv.17907
Letertre, Oriane, et al. "Segmental facial infantile hemangiomas in the era of propranolol: evaluation at six years of age." Journal of the European Academy of Dermatology and Venereology : JEADV vol. (2022). doi: https://doi.org/10.1111/jdv.17907
Letertre O, Boccara O, Prey S, Pedespan JM, Boralevi F, Léauté-Labrèze C. Segmental facial infantile hemangiomas in the era of propranolol: evaluation at six years of age. J Eur Acad Dermatol Venereol. 2022 Jan 09; doi: 10.1111/jdv.17907. Epub 2022 Jan 09. PMID: 35000215.
Copy Download .nbib Format: NLM
Delineating .

Neurology. Genetics

Vegas N, Cavallin M, Maillard C, Boddaert N, Toulouse J, Schaefer E, Lerman-Sagie T, Lev D, Magalie B, Moutton S, Haan E, Isidor B, Heron D, Milh M, Rondeau S, Michot C, Valence S, Wagner S, Hully M, Mignot C, Masurel A, Datta A, Odent S, Nizon M, Lazaro L, Vincent M, Cogné B, Guerrot AM, Arpin S, Pedespan JM, Caubel I, Pontier B, Troude B, Rivier F, Philippe C, Bienvenu T, Spitz MA, Bery A, Bahi-Buisson N.
PMID: 30533527
Neurol Genet. 2018 Nov 07;4(6):e281. doi: 10.1212/NXG.0000000000000281. eCollection 2018 Dec.

OBJECTIVE: To provide new insights into the METHODS: We analyzed the clinical and imaging phenotypes of a cohort of 45 patients with a pathogenic or likely pathogenic RESULTS: A total of 37 CONCLUSIONS: These findings have implications for genetic...

Cite
Vegas N, Cavallin M, Maillard C, et al. Delineating . Neurol Genet. 2018;4(6):e281doi: 10.1212/NXG.0000000000000281.
Vegas, N., Cavallin, M., Maillard, C., Boddaert, N., Toulouse, J., Schaefer, E., Lerman-Sagie, T., Lev, D., Magalie, B., Moutton, S., Haan, E., Isidor, B., Heron, D., Milh, M., Rondeau, S., Michot, C., Valence, S., Wagner, S., Hully, M., Mignot, C., Masurel, A., Datta, A., Odent, S., Nizon, M., Lazaro, L., Vincent, M., Cogné, B., Guerrot, A. M., Arpin, S., Pedespan, J. M., Caubel, I., Pontier, B., Troude, B., Rivier, F., Philippe, C., Bienvenu, T., Spitz, M. A., Bery, A., & Bahi-Buisson, N. (2018). Delineating . Neurology. Genetics, 4(6), e281. https://doi.org/10.1212/NXG.0000000000000281
Vegas, Nancy, et al. "Delineating ." Neurology. Genetics vol. 4,6 (2018): e281. doi: https://doi.org/10.1212/NXG.0000000000000281
Vegas N, Cavallin M, Maillard C, Boddaert N, Toulouse J, Schaefer E, Lerman-Sagie T, Lev D, Magalie B, Moutton S, Haan E, Isidor B, Heron D, Milh M, Rondeau S, Michot C, Valence S, Wagner S, Hully M, Mignot C, Masurel A, Datta A, Odent S, Nizon M, Lazaro L, Vincent M, Cogné B, Guerrot AM, Arpin S, Pedespan JM, Caubel I, Pontier B, Troude B, Rivier F, Philippe C, Bienvenu T, Spitz MA, Bery A, Bahi-Buisson N. Delineating . Neurol Genet. 2018 Nov 07;4(6):e281. doi: 10.1212/NXG.0000000000000281. eCollection 2018 Dec. PMID: 30533527; PMCID: PMC6244024.
Copy Download .nbib Format: NLM
Showing 1 to 6 of 6 entries